Navigation Links
MacroGenics Receives Milestone Payment as Part of Its Global DART™ Alliance with Boehringer Ingelheim
Date:12/20/2011

ROCKVILLE, Md., Dec. 20, 2011 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops next generation antibody therapeutics, announced today that it will receive a milestone payment from Boehringer Ingelheim.  The milestone payment was triggered as part of an agreement executed in October 2010 to discover, develop and commercialize antibody-based therapeutics based on MacroGenics' Dual-Affinity Re-Targeting (DART) platform.  The amount of the milestone payment remained undisclosed.  Therapeutics in the global alliance will be directed against up to ten combinations of molecular targets and may span multiple therapeutic areas, including immunology, oncology, respiratory, cardiometabolic and infectious diseases.  To date, MacroGenics has achieved five pre-clinical milestones across both of its DART collaborations with Boehringer Ingelheim and Pfizer, Inc.

Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics, commented: "We are very encouraged by the progress we've made with this DART candidate in collaboration with Boehringer Ingelheim."  Dr. Koenig continued, "MacroGenics expects to advance multiple product candidates from this alliance in 2012 and beyond."

About MacroGenics
MacroGenics is a private, venture-backed biotechnology company that focuses on the discovery, development and delivery to patients of novel biologics for cancer, autoimmune disorders and infectious diseases. The company has built a fully-integrated set of capabilities in antibody-based product development which supports its innovative pipeline of clinical stage product candidates. MacroGenics' proprietary research is based on three core technology platforms, which include: (1) a leading research capability for screening and targeting cancer stem-like cells; (2) Dual-Affinity Re-Targeting (or DART) bispecific technology, which allows the incorporation of multiple specificities within a single recombinant molecule; and (3) Fc optimization, which enhances antibody-dependent effector functions.  The company has research and development collaborations with multiple, major pharmaceutical companies including Boehringer Ingelheim, Les Laboratoires Servier and Pfizer, Inc.  For more information about MacroGenics, please visit www.macrogenics.com.

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as MacroGenics' ability to raise additional capital, and risks related to its ability to initiate, and enroll patients in, planned clinical trials. You should not place undue reliance on any forward-looking statements. MacroGenics assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by law.

 

 

 


'/>"/>
SOURCE MacroGenics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. MacroGenics Initiates Phase I Clinical Trial of MGAH22 for Patients With HER2-Expressing Solid Tumors
2. MacroGenics Enters Global Research Collaboration and License Agreement with Pfizer
3. MacroGenics Receives NIH Grant Funding of $9.8M for Three Projects; Funding Further Advances DART Platform and Infectious Disease Portfolio
4. MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus
5. Paulo F. Costa Joins MacroGenics Board of Directors
6. MacroGenics Appoints New Vice President of Business Development
7. MacroGenics Raises $25M in Series D-2 Financing
8. Life Technologies Ion Personal Genome Machine Receives San Diegos CONNECT Most Innovative New Product Award
9. Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
10. Watsons Generic Yaz(R) Receives FDA Approval
11. UCSB professor receives award for graphene electronics research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2020)... (PRWEB) , ... February 12, 2020 , ... ... and pharmacovigilance (PV) solutions and services, is adopting Veeva Vault Safety™ ... are a requirement for fast assessment of data, processing of safety information such ...
(Date:2/10/2020)... LAS VEGAS (PRWEB) , ... February 10, 2020 , ... ... Cell Training Course March 13-14th, 2020 in Las Vegas. The course is hands ... procedure too. , For the past few years, the Comprehensive Stem Cell Training Course ...
(Date:2/3/2020)... NEW YORK (PRWEB) , ... February 03, 2020 ... ... Quarterly Business Travel, Financial Services Firm Travel, Law Firm Travel, Technology Industry Travel ... of data findings, listed quarterly. Each Index illustrates the following statistics:, ...
(Date:1/28/2020)... ... January 28, 2020 , ... ... R&D, today announced the release of Genedata Expressionist ® 13.5 at ... implementation of Multi-Attribute Methods (MAM) for characterizing and monitoring the quality of ...
Breaking Biology Technology:
(Date:1/29/2020)... COLLEGE, Pa. (PRWEB) , ... January 29, 2020 ... ... in nuclear receptor and in vitro toxicology testing solutions, has announced a record ... in the upcoming weeks, INDIGO showed more than a twenty percent increase in ...
(Date:1/27/2020)... ... ... On Thursday, February 20, 2020 at 10am EST (3pm GMT/UK), join Gary Saner, ... Global Account Manager Medical Device at PRISYM ID for an informative live ... best practices in creating and submitting product data and best practices in preparing and ...
(Date:1/24/2020)... ... January 24, 2020 , ... Worldwide Business with kathy ireland® ... Stanley Stanbridge and Vice President of Sales and Marketing Jeff Maier to discuss their ... sponsored content on Sunday, Jan. 26, 2020 at 5:30 p.m. EST and internationally on ...
Breaking Biology News(10 mins):